Several new multiple sclerosis drugs, including natalizumab, may be more effective at reducing relapses but still come with serious safety concerns.
Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.
Several microRNA were found to be associated with lesion volume and brain atrophy in multiple sclerosis.
Despite an elevated risk of PML, treatment with natalizumab results in slower disease progression than other treatments.
Patients with both MS and epileptic seizures had a younger age at onset of MS compared with those without seizures.
Researchers report 2 cases of a severe B-cell-mediated CNS disease after treatment with alemtuzumab in patients with multiple sclerosis.
More structured MRI reports may aid in the diagnosis of multiple sclerosis.
It is not clear whether CSF CD27 could provide novel or simply complementary prognostic value in clinically isolated syndrome.
Low levels of neonatal vitamin D may be linked with risk of developing multiple sclerosis.
Previous MRI studies focused on gray matter changes only.
The authors aimed to identify confirmed disability improvement (CDI), which reflects a clinically meaningful change in EDSS score.
Researchers still recommend that patients with MS engage in physical activity for cardiovascular benefits.
Researchers believe that the drug may help prevent MS, since there was a 96% reduction in harmful clusters of B cells.
Notably, patients who had documented psychotic and psychiatric disorders were more likely to be diagnosed with a demyelinating disease.
Over 90% of participants achieved NEDA-3 after being transitioned to dimethyl-fumarate from natalizumab.
The relationship between microstructural damage in NAWM and clinical measures was less clear, suggesting another mechanism.
Researchers examined whether the cognitive reserve hypothesis could predict cognitive decline, gray matter volume changes, and white matter volume changes in MS patients.
High-fat diets may increase the risk of relapse in children with MS, while high-vegetable diets may be protective.
Six polymorphisms were found to be strongly associated with vitamin D levels in the patient population.
Axon diameter dynamics may serve as a novel biomarker for MS disease course.
Patients at the greatest risk of disability progression were older than 12 years, and had minimal exposure to DMTs.
Higher BMI and lipid levels were associated with greater risk of relapse and disability progression.
A proper MS diagnosis can only be made after obtaining imaging from the entire brain and understanding the clinical context.
Several strategies for clinical practice and research may reduce the cost of MS treatment while maintaining efficacy.
The findings from the extension study support prior research that showed the benefits of early treatment.
Routine evaluation with MRI appeared to have no clinical benefit over time.
It has been proposed that the gut microbiome may be an important environmental risk factor in MS.
Among study participants, relapse rate actually decreased from the first to second pregnancy.
Differences in gut bacteria were apparent between patients with active RRMS and those in remission.
While supplementation has produced a positive response in disease activity, adverse events based on dosing are concerning.
Neurology Advisor Articles
- Cannabis: Current Evidence and Research Recommendations
- Addressing Gender Differences in Concussion Diagnosis and Treatment
- Sphenopalatine Ganglion Stimulation May Help Treat, Prevent Cluster Headache
- Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant
- Maternal Antiepileptic Use and Risk for Major Congenital Malformations in Offspring
- Persistent Asthma May Increase Migraine Risk in Children
- Updated Guidelines for Treatment of Low Back Pain
- Antiretroviral Therapy May Improve Neurodevelopmental Outcomes in HIV-Infected Infants
- Head Impacts in Soccer Lead to Moderate to Severe CNS Symptoms
- The Handoff: Your Week in Neurology News - 2/16/17